As­traZeneca ax­es li­cense agree­ment with Aridis, plac­ing Eu­rope-fund­ed PhI­II on hold

As­traZeneca is scrap­ping its li­cense agree­ment with Aridis Phar­ma­ceu­ti­cals on March 30, the British Big Phar­ma told the biotech last week, send­ing a Eu­ro­pean-fund­ed Phase III in­to stor­age.

With the li­cense ter­mi­nat­ed for AR-320, al­so known as su­vra­tox­um­ab, Aridis can no longer con­tin­ue a late-stage clin­i­cal tri­al test­ing the mon­o­clon­al an­ti­body as a pre­emp­tive treat­ment for me­chan­i­cal­ly ven­ti­lat­ed pa­tients in in­ten­sive care who are col­o­nized with S. au­reus. The SAATEL­LITE-2 tri­al kicked off in Sep­tem­ber and was ex­pect­ed to en­roll 564 pa­tients who don’t have ven­ti­la­tor-as­so­ci­at­ed pneu­mo­nia, or VAP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER